Forever Labs will dedicate resources to continue pioneering stem cell research breakthroughs and accelerate brand development.
Founded in 2015, Forever Labs is transforming the healthcare industry by preserving healthy stem cells for future therapies that combat age-related diseases, as well as aging itself.
Its proprietary procedure involves a certified Forever Labs physician collecting one's mesenchymal stem cells (MSCs), which have the ability to stimulate tissues to grow and repair themselves when most needed.
After a brief outpatient procedure, the stem cells are cryogenically frozen and safely stored agnostically in an FDA-compliant clinical-grade biorepository until needed.
Forever Labs was created to preserve healthy stem cells to later rejuvenate one's MSC population to significantly delay the onset of those age-related diseases and extend a healthy lifespan.
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Lupin launches Dasatinib tablets in US market
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA
FDA approves Tenpoint Therapeutics' YUVEZZI as first dual-agent eye drop for presbyopia
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
WuXi Biologics collaborates with Sinorda Biomedicine for antibody development
Biogen's litifilimab receives FDA Breakthrough Therapy Designation for CLE
Glaukos receives FDA approval for repeat administration of iDose TR
Guerbet's contrast agent Elucirem approved by European Commission in children from birth
Spine Innovation's LOGIC Titanium Implant System receives US FDA 510(k) market approval